One of the main goals of Life4me+ — is to prevent new cases of HIV and other STIs, hepatitis C and tuberculosis.

The app helps to establish anonym communication between physicians and HIV-positive people. It allows you to conveniently organize your medication intake timetable and set concealed and personalized reminders.

FDA approves first once-monthly buprenorphine injection

6 December 2017 11:52

The US Food and Drug Administration (FDA) announced it has approved Sublocade, a once-monthly buprenorphine injection for moderate to severe opioid use disorder (OUD).

Current buprenorphine-based treatments for OUD employ an oral mode of administration and require daily intake, thus posing the issue of medication adherence. These treatments are also available in the form of an implant (Probuphine), which provides stable delivery of low-dose buprenorphine over a 6-month period.

The agency's commissioner, Scott Gottlieb, MD, noted the importance of providing an array of treatment options for OUD. "Everyone who seeks treatment for opioid use disorder deserves the opportunity to be offered the treatment best suited to the needs of each individual patient, in combination with counseling and psychosocial support, as part of a comprehensive recovery plan," he said.

Sublocade (RBP-6000) allows the sustained delivery of buprenorphine over a 1-month period, thanks to the Atrigel Delivery System, which, on subcutaneous injection, forms a solid deposit, subsequently broken down to steadily release the drug.

In a study investigating the efficacy of RBP-6000 the treatment was found to reduce "drug-liking" and demonstrated the safety and tolerability of the treatment for patients ages 17 to 65 years. Clinical studies showed that patients treated with Sublocade had fewer weeks with positive urine tests and self-reported opioid use vs patients receiving placebo.

Latest News

DIY faecal transplants carry risks including HIV and hepatitis

Faecal transplants have been used in medical settings to tackle superbugs, but following YouTube videos at home is too risky, say researchers.

16 February 15:30

Gilead's total revenues were $26.1 billion in 2017

For the fourth quarter 2017, Gilead Sciences total revenues were $5.9 billion. For the full year 2017, total revenues were $26.1 billion. HIV and HBV product sales for the full year 2017 were $14.2 billion. Genvoya represents the most successful HIV launch in the U.S. and ...

16 February 09:31

Key vaginal bacteria identified that increase HIV risk in women

Women's risk of HIV significantly associated with key bacteria and their abundance in the vagina.

15 February 16:35

Experimental Drug Kills Flu Virus in a Single Day

Shionogi developed baloxavir marboxil by leveraging discoveries made in anti-HIV drugs, targeting a different kind of enzyme and preventing cells from susceptibility to virus infection in the first place.

15 February 13:27